|Bid||8.46 x 3600|
|Ask||8.50 x 100|
|Day's Range||8.43 - 9.03|
|52 Week Range||4.10 - 15.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 2, 2018 - Apr 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.80|
Insys (INSY) is taking strategic steps to restore stakeholder confidence. The company aims to achieve one NDA (or new drug application) per year over the next five years. Insys is targeting treatments for orphan diseases, neurological diseases like pediatric epilepsy, genetic conditions like Prader-Willi syndrome, and treatments for secondary allergic reactions, anorexia, and products for opioid overdose.
Should You Jump on the Marijuana Bandwagon? Investors interested in accessing the marijuana industry have several options. In the US, Scotts Miracle-Gro (SMG) has invested in companies that are positioned to serve the cannabis market.
In December 2016, the U.S. Attorney’s Office for the District of Massachusetts issued an indictment against six former Insys (INSY) employees, which included the company’s former president, CEO, and director Michael Babich. This indictment was on charges including racketeering conspiracy, conspiracy to commit mail fraud, conspiracy to commit wire fraud, and conspiracy to violate the anti-kickback statute.
Thus, interaction with government agencies occurs regularly. Insys (INSY) has been a part of several government investigations recently. Insys received a subpoena in December 2013 from the inspector general of HHS for an investigation of potential violations that involved HHS programs.
Insys’s (INSY) net revenues decreased from $57.7 million in 3Q16 to $30.7 million in 3Q17, which was attributable to a decrease in Subsys sales. As a result, the gross profit of the company decreased to $23.1 million in 3Q17 as compared with $53 million for 3Q16. The general and administrative expenses of the company decreased to $15.7 million in 3Q17 as compared with $17.7 million for 3Q16.
Should You Jump on the Marijuana Bandwagon? Investing in the marijuana industry—at least in its current stage in the US—certainly comes with its own set of risks. In the preceding part of this series, we discussed how the marijuana plant contains CBD (cannabidiol), which is used for medicinal (XLV) purposes.
A former Insys Therapeutics Inc employee accused of engaging in a scheme to pay medical practitioners kickbacks to prescribe a fentanyl-based treatment is seeking to bar U.S. prosecutors from referring to the "opioid crisis" at his trial. Lawyers for Jeffrey Pearlman, a former district sales manager at the drugmaker, in a motion filed on Wednesday asked a federal judge in Connecticut to bar references at his trial to the crisis and evidence about the dangers opioids pose. "This prejudice would only be amplified if the government were to elicit testimony or make arguments regarding the opioid crisis or the over-prescription of opioids," Pearlman's lawyers wrote.
As marijuana legalization begins to slowly roll out state by state, it follows that marijuana-based businesses have cropped up, and many are trying their hand in the public markets. Regrettably, CANN is losing more and more money on marijuana services every year and is also burning cash.
NEW YORK, Jan. 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Insys ...
NEW YORK, NY / ACCESSWIRE / January 5, 2018 / On Thursday, all three major indexes rose for the third consecutive day, with the Dow Jones crossing the 25,000 plateau for the first time ever. The Dow Jones ...
PHOENIX, Jan. 03, 2018-- INSYS Therapeutics, Inc., announced today that Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will present at the 36 th annual ...
Insys Therapeutics shares have more than doubled over the past month, but traders will be closely watching these key levels.